ArticleJournal for immunotherapy of cancer2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory.
Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Social determinants of health in studies using PROMs to assess toxicities associated with immune checkpoint inhibitor treatment: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.Scientific reports · 2022Trial
- Study Protocol to Characterize Symptom Experience During Immune Checkpoint Inhibitor Therapy for Cutaneous Melanoma.Nursing research · 2026Article
- Psychometric Validation of a new module of MD Anderson Symptom Inventory (MDASI) for Patients with Upper Gastrointestinal Cancers: MDASI-UGI-Surg.Annals of surgical oncology · 2026Article
- Patient-Reported Symptom and Symptom Clusters During Immune Checkpoint Inhibitor Therapy for Cancer Patients: A Cross-Sectional Survey.Health science reports · 2026Article
- Psychometric validation of Chinese version of the immunotherapy of the M.D. Anderson Symptom Inventory for Early-Phase Trials module in a multi-cancer cohort.Frontiers in immunology · 2026Article
- Psychometric properties of patient-reported outcome measures for symptom assessment in patients with cancer receiving immunotherapy: A systematic review following the COSMIN 2.0 guidelines.Asia-Pacific journal of oncology nursing · 2025Review
- Development and validation of the self-report symptom inventory of immune-related adverse events in patients with lung cancer.Asia-Pacific journal of oncology nursing · 2024Article
- Article
- Patient-reported outcome measure (PROM) programs for monitoring symptoms among patients treated with immunotherapy: a scoping review.JNCI cancer spectrum · 2024Article
- Translation and validation of chinese version of MDASI immunotherapy for early-phase trials module: a cross-sectional study.BMC nursing · 2023Article
- Novel classes of immunotherapy for breast cancer.Breast cancer research and treatment · 2022Review
- Associations between the gut microbiome and fatigue in cancer patients.Scientific reports · 2021Article
- Strategies for improving the management of immune-related adverse events.Journal for immunotherapy of cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 1 institution in 1 country.
Funding
Abstract
introductionImmunotherapies have revolutionized the treatment of various cancers, but little is known about their symptomatic toxicity. Assessing these symptoms is best accomplished by asking the patients themselves. However, such reports are subjective and may face challenges as bonafide scientific data. Demonstrating the validity of symptom assessment tools, mainly through the reduction of measurement errors, has the potential to improve patient care if these tools are widely adopted. To that end, we present herein the psychometric properties of the Immunotherapy for Early-Phase Trials module of the MD Anderson Symptom Inventory (MDASI-Immunotherapy EPT) in patients receiving various immunotherapies in early phase trials at a major cancer center.
methodsOne hundred forty-five patients completed the inventory at baseline, with 85 of them also doing so after 9 weeks of treatment. The mean (±SD) age of the patients was 57.0±12.9 years. Also, 56% of the patients were women, 79% identified as white, and 49% had at least some college education.
resultsThe internal consistency reliability of the MDASI-Immunotherapy EPT was excellent, as the Cronbach's alphas for all of its subscales were at least 0.88 (range 0.88-0.95). Known-group validity based on Eastern Cooperative Oncology Group performance status groupings was excellent at 9 weeks after the start of an immunotherapy trial for the MDASI-Immunotherapy EPT severity (effect size, 0.96) and interference (effect size, 0.82) subscales. We found substantial changes in the symptom items difficulty remembering (effect size, -0.85), fever and/or chills (effect size, -0.63), disturbed sleep (effect size, -0.52), diarrhea (effect size, -0.42), and swelling of hands, legs, or feet (effect size, -0.39).
conclusionsIn conclusion, the MDASI-Immunotherapy EPT is a valid, reliable, and sensitive tool for measuring symptomatic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.